It is difficult to diagnose neurodegenerative diseases (NDDs), such as Parkinson’s disease and Alzheimer’s disease, because no methods are available to identify preclinical biomarkers. The importance of protein misfolding into oligomeric and fibrillar aggregates in the onset and evolution of NDDs highlights the demand for structural biomarker-based diagnostics. Researchers created an immunoassay-…
